N H 0 0 4 P R O G R A M S U M M A R Y – A P R I L 2 0 0 9 L I C E N S I N G @ N E U R O H E A L I N G . C O M 1
N E U R O H E A L I N G P H A R M A C E U T I C A L S I N C .
6 1 7 . 3 3 1 . 4 1 1 1 - W W W . N E U R O H E A L I N G . C O M
5 0 U N D I N E R D , U N I T # 1 - N E W T O N , M A 0 2 1 3 5
A Supportive Care Product for
Parkinson’s Disease Patients
NH004 – Treatment for Sialorrhea
NH004 is a novel treatment to control the symptoms of sialorrhea (excessive drooling) in patients
suffering from Parkinson’s Disease and other motor disorders. NH004’s active ingredient is the
anticholinergic drug tropicamide, delivered in a thin film designed to adhere and slowly dissolve
within the oral cavity to allow the drug to reach the underlying salivary gland, thereby reducing
saliva secretions. The advantages of NH004 include local bioavailability with low systemic
exposure, rapid onset of action and, importantly, convenience of use for patients. The active
agent has a long history of safe topical ophthalmologic use in humans.
NH004 is currently in a double-blind phase II clinical testing in Parkinson’s Disease patients, and
is expected to be completed by the end of 2009. A planned interim analysis has indicated a
difference in reducing sialorrhea between the NH004 treated and placebo groups. This clinical
trial is being funded by the Michael J Fox Foundation.
Mechanism of Action
The active pharmaceutical ingredient in NH004 is tropicamide, a synthetic tertiary amine
anticholinergic agent acting as a non-selective blockage to muscarinic receptors. Tropicamide is a
fast-acting compound currently approved for use by the FDA as an ophthalmic solution for
diagnostic procedures and surgeries. In sialorrhea, tropicamide acts by blocking the acetylcholine
receptors of the salivary glands.
Active Ingredient: Tropicamide
CAS number: 1508-75-